COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 1 for:    Vedolizumab-4014
Previous Study | Return to List | Next Study

Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis (ENTERPRET)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03029143
Recruitment Status : Active, not recruiting
First Posted : January 24, 2017
Last Update Posted : February 10, 2020
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : May 29, 2020
Estimated Study Completion Date : October 30, 2020